Food and Drug Administration: approved for use in all hospitalized patients with new crown

category:Internet
 Food and Drug Administration: approved for use in all hospitalized patients with new crown


On August 21 local time, the latest clinical data of radcivir were published in the Journal of the American Medical Association (JAMA). The results showed that there was no significant effect on moderate patients with new crown and the course of disease could not be shortened. Although the data show that moderate patients are more likely to improve after five days of treatment with radcivir than patients receiving standard treatment, the clinical significance of the benefit remains uncertain, the researchers said.

The FDA said in a press release that the agency has concluded that redcivir may be effective in treating new crowns, with potential benefits outweighing risks.

Source: interface news editor: Qiao JunJing_ NBJ11279